{"entity":{"id":"nct07615101","kind":"trial","name":"Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.","aka":[],"tldr":"A phase 3 trial of 68-Ga-NYM032 in prostate cancer, run by Norroy Bioscience Co., LTD, now recruiting.","summary":"Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer. is a phase 3 interventional study registered as NCT07615101 by Norroy Bioscience Co., LTD, with 365 participants planned, started 2026-08-06 and due to reach its primary completion in 2027-06-30. Interventions recorded: 68-Ga-NYM032.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07615101","url":"https://clinicaltrials.gov/study/NCT07615101"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07615101","phase":"3","setting":"Open-label, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.","sponsor":"Norroy Bioscience Co., LTD","enrolled":365,"outcomes":[]},"route":"/trials/nct07615101/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}]}}